Neue Biomarker im Serum und im Urin zur Detektion des Prostatakarzinoms

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Aktuelle Urologie

• Publication date

  2015-03-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/s-0034-1398544PMID 25897535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer diagnosis.

  2015cited by this paper
• The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL

  2014cited by this paper
• Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer—A large nested case–control study within the JANUS cohort in Norway

  2014cited by this paper
• Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

  2014cited by this paper
• Risk stratification in prostate cancer screening

  2013cited by this paper
• Quantified KLK15 Gene Expression Levels Discriminate Prostate Cancer From Benign Tumors and Constitute a Novel Independent Predictor of Disease Progression

  2013cited by this paper
• Risk stratification in prostate cancer screening

  2013cited by this paper
• Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?

  2013cited by this paper
• PSA, PCA3 and the phi losophy of prostate cancer management

  2013cited by this paper
• From prostate‐specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer

  2013cited by this paper
• Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer.

  2013cited by this paper
• PCA3 and PCA3-Based Nomograms Improve Diagnostic Accuracy in Patients Undergoing First Prostate Biopsy

  2013cited by this paper
• PCA3 in the detection and management of early prostate cancer

  2013cited by this paper
• Prostate Health Index (PHI): golden bullet or just another prostate cancer marker?

  2013cited by this paper
• Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer.

  2013cited by this paper
• Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.

  2013cited by this paper
• Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.

  2013cited by this paper
• Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

  2013cited by this paper
• Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection

  2013cited by this paper
• Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer.

  2013cited by this paper
• Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients

  2013cited by this paper
• Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer

  2013cited by this paper
• Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml

  2013cited by this paper
• Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.

  2013cited by this paper
• Urinary biomarkers for prostate cancer: a review.

  2013cited by this paper
• Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy

  2013cited by this paper
• Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

  2013cited by this paper
• Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration.

  2013cited by this paper
• Galectin-3: a possible complementary marker to the PSA blood test

  2013cited by this paper
• Diagnostic significance of [−2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range

  2013cited by this paper
• PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

  2013cited by this paper
• Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.

  2013cited by this paper
• Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy

  2013cited by this paper
• Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI

  2013cited by this paper
• Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis

  2013cited by this paper
• Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

  2013cited by this paper
• Toward the detection of prostate cancer in urine: a critical analysis.

  2013cited by this paper
• Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

  2013cited by this paper
• Sarcosine as a Potential Prostate Cancer Biomarker—A Review

  2013cited by this paper
• Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.

  2012cited by this paper
• Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.

  2012cited by this paper
• Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml

  2012cited by this paper
• Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.

  2012cited by this paper
• Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.

  2012cited by this paper
• Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis

  2012cited by this paper
• Zinc α2‐glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer

  2012cited by this paper
• Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.

  2012cited by this paper
• EPCA-2: a highly specific serum marker for prostate cancer.

  2012cited by this paper
• Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

  2012cited by this paper
• Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy.

  2012cited by this paper
• Plasma sarcosine does not distinguish early and advanced stages of prostate cancer.

  2012cited by this paper
• Spondin-2 (SPON2), a More Prostate-Cancer-Specific Diagnostic Biomarker

  2012cited by this paper
• Chronic prostatitis does not influence urinary PCA3 score

  2012cited by this paper
• Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

  2011cited by this paper
• Contemporary role of prostate cancer gene 3 in the management of prostate cancer

  2011cited by this paper
• Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.

  2011cited by this paper
• Tumour markers in prostate cancer III: Biomarkers in urine

  2011cited by this paper
• A multiplex model of combining gene‐based, protein‐based, and metabolite‐based with positive and negative markers in urine for the early diagnosis of prostate cancer

  2011cited by this paper
• Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

  2011cited by this paper
• External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome

  2011cited by this paper
• Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

  2011cited by this paper
• Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

  2011cited by this paper
• Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.

  2011cited by this paper
• Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.

  2011cited by this paper
• Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.

  2011cited by this paper
• A Three‐Gene panel on urine increases PSA specificity in the detection of prostate cancer

  2011cited by this paper
• A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

  2011cited by this paper
• [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.

  2010cited by this paper
• A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France

  2010cited by this paper
• KLK15 is a prognostic marker for progression‐free survival in patients with radical prostatectomy

  2010cited by this paper
• A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness

  2010cited by this paper
• Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.

  2010cited by this paper
• Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test.

  2010cited by this paper
• Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.

  2010cited by this paper
• Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.

  2010cited by this paper
• The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

  2010cited by this paper
• Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).

  2010cited by this paper
• Predictive value of PCA3 in urinary sediments in determining clinico‐pathological characteristics of prostate cancer

  2010cited by this paper
• Detection of complexes between prostate-specific antigen and protease inhibitors in plasma.

  2010cited by this paper
• Serum sarcosine is not a marker for prostate cancer

  2010cited by this paper
• Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

  2010cited by this paper
• „Dangerous liaisons“ im Prostatakarzinom

  2010cited by this paper
• External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

  2010cited by this paper
• Urine markers in monitoring for prostate cancer

  2010cited by this paper
• PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

  2010cited by this paper
• Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

  2009cited by this paper
• A [‐2]proPSA‐based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases

  2009cited by this paper
• FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST

  2009cited by this paper
• PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome

  2009cited by this paper
• Neue Biomarker und Anwendung multivariater Modelle zur Detektion des Prostatakarzinoms

  2009cited by this paper
• Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

  2009cited by this paper
• Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer

  2009cited by this paper
• Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort

  2009cited by this paper
• New markers and multivariate models for prostate cancer detection.

  2009cited by this paper
• Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.

  2009cited by this paper
• A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.

  2008cited by this paper
• PCA3: a molecular urine assay for predicting prostate biopsy outcome.

  2008cited by this paper
• Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.

  2008cited by this paper
• An artificial neural network for five different assay systems of prostate‐specific antigen in prostate cancer diagnostics

  2008cited by this paper
• Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

  2008cited by this paper

• Hydrogen Sulfide Biology and Its Role in Cancer

  2022cites this paper
• Molecular Functions of Hydrogen Sulfide in Cancer

  2021cites this paper
• Serum and Urine Levels of Sarcosine in Benign Prostatic Hyperplasia and Newly Diagnosed Prostate Cancer Patients

  2020cites this paper
• Hydrogen Sulfide: Emerging Role in Bladder, Kidney, and Prostate Malignancies

  2019cites this paper
• Expression and clinical significance of Caveolin-1 in prostate Cancer after transurethral surgery

  2018cites this paper
• Studies on the serum peptide fingerprint of bacterial bloodstream infection by matrix-assisted laser desorption ionization time of flight mass spectrometry

  2017cites this paper
• Hydrogen Sulfide Signaling Axis as a Target for Prostate Cancer Therapeutics

  2016cites this paper